Immunotherapy strategies for chemotherapy-resistant high-grade serous ovarian cancer
Project 1
This project uses combined immunotherapy approaches to boost and sustain tumor-fighting T cells in people with chemotherapy-resistant high-grade serous ovarian cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11146381 on NIH RePORTER |
What this research studies
If you join, researchers will combine several immune-based treatments—such as checkpoint blockers, engineered T cells, and tumor-targeting viruses—to increase and sustain tumor-specific T cells against your ovarian cancer. They will work to reduce immune-suppressing cells, recruit dendritic cells that help present tumor targets, and improve tumor blood vessel function so immune cells can reach tumors. Lab testing on tumor samples and preclinical models will guide which combinations look most promising, and the best approaches will be advanced toward use in patients with recurrent, chemo-resistant disease. The goal is durable tumor shrinkage by training your immune system to find and kill the cancer.
Who could benefit from this research
Good fit: People with recurrent or progressive high-grade serous ovarian cancer that is resistant to standard chemotherapy would be the most likely candidates.
Not a fit: Patients with other ovarian cancer subtypes, early-stage disease already controlled by standard treatments, or those unable to tolerate immunotherapy may not directly benefit from this project.
Why it matters
Potential benefit: Could provide long-lasting tumor control and shrinkage for patients whose high-grade serous ovarian cancer no longer responds to chemotherapy.
How similar studies have performed: Immune therapies like checkpoint inhibitors and adoptive T cells have had major successes in cancers such as melanoma and lung cancer, but similar approaches have rarely produced durable control in high-grade serous ovarian cancer, so this combination approach is promising but not yet proven.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Odunsi, Kunle — Roswell Park Cancer Institute Corp
- Study coordinator: Odunsi, Kunle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.